Last reviewed · How we verify
NCT07356063: SEE-NMD
Self-Efficacy Enhancement Using a Multicomponent Support Group for Caregivers of Children With DMD/SMA
NA trial testing Multicomponent Support Group in Duchenne Muscular Dystrophy (DMD) in 30 participants. Not yet recruiting.
23 March 2026
Quick facts
| Lead sponsor | Aga Khan University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 30 |
| Start date | 23 February 2026 |
| Primary completion | 23 March 2026 |
| Estimated completion | 23 May 2026 |
Drugs / interventions tested
- Multicomponent Support Group
Conditions studied
- Duchenne Muscular Dystrophy (DMD) — all drugs for Duchenne Muscular Dystrophy (DMD) →
- Spinal Muscular Atrophy (SMA) — all drugs for Spinal Muscular Atrophy (SMA) →
Sponsor
Aga Khan University
Who can join
Eligibility, any sex, with Duchenne Muscular Dystrophy (DMD) or Spinal Muscular Atrophy (SMA). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if providing a multicomponent intervention improves the confidence of caregivers of children with DMD or SMA. The main question it aims to answer is: Does this intervention increase their self-efficacy scores over 8 weeks time? Researchers will compare scores at baseline (pre intervention) and after 8 weeks (post intervention)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07356063
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Duchenne Muscular Dystrophy (DMD)
Currently open trials in the same condition.
- NCT07038824 — A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficac · Phase 1, PHASE2 · recruiting
- NCT07129954 — Fear of Falling in Muscular Dystrophy · NA · recruiting
- NCT07037862 — A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficac · Phase 1, PHASE2 · recruiting
- NCT06755138 — Research on the Relationship Between Scoliosis, Pain, Quality of Life, and Trunk Muscle Compensation Patterns Among Pati · recruiting
- NCT06773988 — Follow-up of NIV At Home in Patients with Duchenne Muscular Dystrophy · recruiting
Other Aga Khan University trials
Trials by the same sponsor.
- NCT07475793 — Image Guided Genicular Nerve Radiofrequency Ablation for Chronic Knee Osteoarthritis · NA · not yet recruiting
- NCT07197684 — Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surg · NA · not yet recruiting
- NCT07451951 — Effectiveness of SQLNS vs MQLNS for Prevention of Undernutrition in Children 6-12 Months · NA · not yet recruiting
- NCT07357350 — Effectiveness of Pain Management Interventions in Patients With Abdominal and Pelvic Cancer · not yet recruiting
- NCT07395999 — Effectiveness of Pain Management Interventions in Patients With Chronic Cancer Pain · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07356063 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aga Khan University
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07356063.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing